Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
Tab Title Description
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:* 18 years or older at the time of Ph+-CML-CP diagnosis.* Receiving TKI treatment (asciminib, bosutinib, dasatinib, imatinib, or nilotinib) in routine medical care either as initial therapy or after 1 prior TKI therapy.* Receiving treatment at US and US territories (i.e., Puerto Rico) medical practice (e.g. community-based, office-based, hospital-based, academic).* Signed informed consent form (ICF) prior to participation in the study including agreement to be tokenized so that the patient's anonymized RWD (EMRs and/or claims data) can be accessed.Exclusion Criteria:* Active participation in an interventional trial that may influence the management of their Ph+-CML-CP disease.* Currently being treated with a CML TKI in 3L or beyond.* Known presence of T315I mutation.* Currently in TFR phase and are not on active CML TKI therapy.* Previously received treatment with a prior stem cell transplant* Pregnant or nursing (lactating) female.
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic principal investigator
Contact us for the latest status
Cancer Center Clinical Trials Referral Office
(855) 776-0015
James Foran, M.D.